20-F
Annual Report (Foreign)
Cordyceps Sunshine Biotech Holdings Co., Ltd. RAJAF
0001213900-26-057774
- Filed
- May 15, 2026 12:00 AM ET
- Period of report
- —
Restated figures. One or more values in this filing restate previously reported amounts.
On SEC.gov
Financials in this filing
| Metric | Period | Value |
|---|---|---|
| Shares Diluted | FY 2025 · Dec 31, 2025 | 111.12M sh |
| Shares Diluted | FY 2025 · Dec 31, 2024 | 111.12M sh |
| Shares Outstanding | FY 2025 · Dec 31, 2025 | 111.12M sh |
| Operating Cash Flow | FY 2025 · Dec 31, 2025 | −$35.85K |
| Operating Cash Flow | FY 2025 · Dec 31, 2024 | $312.01K |
| Cash And Equivalents | FY 2025 · Dec 31, 2025 | $3.2K |
| Cash And Equivalents | FY 2025 · Dec 31, 2024 | $37.28K |
| Stockholders Equity | FY 2025 · Dec 31, 2025 | −$534.55K |
| Stockholders Equity | FY 2025 · Dec 31, 2024 | −$375.54K |
| Current Liabilities | FY 2025 · Dec 31, 2025 | $5.19M |
| Current Liabilities | FY 2025 · Dec 31, 2024 | $4.99M |
| Total Liabilities | FY 2025 · Dec 31, 2025 | $5.19M |
| Total Liabilities | FY 2025 · Dec 31, 2024 | $5M |
| Current Assets | FY 2025 · Dec 31, 2025 | $997.74K |
| Current Assets | FY 2025 · Dec 31, 2024 | $601.6K |
| Total Assets | FY 2025 · Dec 31, 2025 | $4.66M |
| Total Assets | FY 2025 · Dec 31, 2024 | $4.62M |
| Eps Diluted | FY 2025 · Dec 31, 2025 | $0.00 |
| Eps Diluted | FY 2025 · Dec 31, 2024 | $0.00 |
| Eps Basic | FY 2025 · Dec 31, 2025 | $0.00 |
| Eps Basic | FY 2025 · Dec 31, 2024 | $0.00 |
| Net Income | FY 2025 · Dec 31, 2025 | −$154.82K |
| Net Income | FY 2025 · Dec 31, 2024 | −$226.26K |
| Operating Income | FY 2025 · Dec 31, 2025 | −$141.13K |
| Operating Income | FY 2025 · Dec 31, 2024 | −$183.91K |
| Gross Profit | FY 2025 · Dec 31, 2025 | $760.74K |
| Gross Profit restated | FY 2025 · Dec 31, 2024 | $906.48K |
| Cost Of Revenue | FY 2025 · Dec 31, 2025 | $484.61K |
| Cost Of Revenue restated | FY 2025 · Dec 31, 2024 | $347K |
| Revenue | FY 2025 · Dec 31, 2025 | $1.25M |
| Revenue | FY 2025 · Dec 31, 2024 | $1.25M |
| Capex | FY 2025 · Dec 31, 2024 | $349.24K |